Moderna and Merck’s mRNA cancer vaccine meets Phase 3 endpoints, sending Moderna shares sharply higher 🧬 Moderna and Merck said their personalized mRNA vaccine, intismeran autogene, combined with Keytruda met both the primary recurrence-free survival endpoint and the key secondary distant metastasis-free survival endpoint in the Phase 3 INTerpath-001 trial involving 1,137 patients with surgically resected melanoma. 📈 The result marks the first Phase 3 success for an mRNA-based cancer therapy and an individualized neoantigen vaccine, reinforcing the positive signal previously seen in the Phase 2b study. 💹 Market reaction was strong, with Moderna shares rising around 90–100%+ in premarket trading, while Merck gained roughly 6–9%. ⚠️ However, detailed data such as the hazard ratio and absolute benefit have not yet been released, while overall survival remains under follow-up. The longer-term impact will depend on the full dataset and regulatory progress. #Biotech $MRNAon $MRKX $BNB